Relationship Between Self-compassion and Treatment Adherence in Schizophrenic Spectrum Disorders

NCT05566015 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2023-07-20

No results posted yet for this study

Summary

Treatment adherence is defined by the World Health Organisation (WHO) as the extent to which the patient's history of therapeutic drug-taking coincides with the prescribed treatment. In patients suffering from psychiatrical diseases, especially in those who are suffering from schizophrenic spectrum disorders, the quality of treatment adherence has to be improved. Indeed, non adherance to anti-psychotic treatment increases the risk of hospitalization, of substance use, violent behaviour and of functionnal and cognitif impairment. Selfcompassion, which involves being touched by and open to one's own suffering and to heal oneself with kindness and without judgement and self-criticism has never beed studied as a possible factor infuencing treatment adherence.

This study aims to evaluate if a link between selfcompassion and treatment adherence exists in patients suffering from schizophrenic spectrum disorders.

Conditions

  • Treatment Adherence
  • Selfcompassion
  • Schizophrenic Spectrum Disorder

Interventions

OTHER

questionnaire

self-administered questionnaires as well as clinical assessment of schizophrenia symptoms and depression.

Sponsors & Collaborators

  • Crysalid center Clermont de l'Oise

    collaborator UNKNOWN
  • CMP de Montataire

    collaborator UNKNOWN
  • CMP de Chambly

    collaborator UNKNOWN
  • CMP de Clermont de l'Oise

    collaborator UNKNOWN
  • CMP de st Just en Chaussée

    collaborator UNKNOWN
  • CMP de Senlis

    collaborator UNKNOWN
  • CMP de Crepy en Valois

    collaborator UNKNOWN
  • CMP de Pont St Maxence

    collaborator UNKNOWN
  • CMP de Chantilly

    collaborator UNKNOWN
  • CMP de Creil

    collaborator UNKNOWN
  • Centre Hospitalier Universitaire, Amiens

    lead OTHER

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-26
Primary Completion
2023-07-01
Completion
2023-07-01

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05566015 on ClinicalTrials.gov